Logo

The NMPA Accepts Everest Medicine's IND Application for Zetomipzomib to Treat Immune Mediated Disorders

Share this
Everest Medicine

The NMPA Accepts Everest Medicine's IND Application for Zetomipzomib to Treat Immune Mediated Disorders

Shots:

  • Everest Medicines's IND application for zetomipzomib was accepted by China's NMPA for the treatment of patients with immune-mediated disorders, incl. lupus nephritis (LN)
  • Earlier the result of the P-II study at 25 & 37 week showed an overall renal response rate of 64.7% & 88.2%, the mean reduction in UPCR from baseline was 57.0% & 83.0% while eGFR remained stable during treatment. Additionally, it also showed a favorable safety & tolerability profile 
  • Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor. Everest Medicines, in collaboration with Kezar Life Sciences, is set to participate in the P-IIb (PALIZADE) trial

Ref: PR Newswire | Image: Everest Medicines

Related News:- Kezar Life Sciences Entered into a Collaboration and License Agreement with Everest Medicines for Zetomipzomib to Treat Lupus Nephritis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions